Roche's fenebrutinib shows promise in treating relapsing multiple sclerosis with no disability progression over 96 weeks. Promising results were presented at CMSC Annual Meeting, with ongoing Phase 3 trials. Roche's $50 billion U.S.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing